Evidence map›Paper›PMID 30952898›Full record

ArticleScientific reports2019

Functional evaluation of PDGFB-variants in idiopathic basal ganglia calcification, using patient-derived iPS cells.

Shin-Ichiro Sekine, Masayuki Kaneko, Masaki Tanaka, Yuhei Ninomiya, Hisaka Kurita, Masatoshi Inden, Megumi Yamada, Yuichi Hayashi, Takashi Inuzuka, Jun Mitsui and 14 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The Genetics of Primary Familial Brain Calcification: A Literature Review.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 1 country.

Shin-Ichiro SekineLaboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.
Masayuki KanekoLaboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.ORCID http://orcid.org/0000-0002-0477-0171
Masaki TanakaDepartment of Neurology, The University of Tokyo, Tokyo, Japan.
Yuhei NinomiyaLaboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.
Hisaka KuritaLaboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.
Masatoshi IndenLaboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan.
Megumi YamadaDepartment of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan.
Yuichi HayashiDepartment of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan.
Takashi InuzukaDepartment of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan.
Jun MitsuiDepartment of Neurology, The University of Tokyo, Tokyo, Japan.
Hiroyuki IshiuraDepartment of Neurology, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2975-7309
Atsushi IwataDepartment of Neurology, The University of Tokyo, Tokyo, Japan.
Hiroto FujigasakiDepartment of Neurology, Tokyo Metropolitan Bokuto Hospital, Tokyo, Japan.
Hisamitsu TamakiDepartment of Pediatrics, Tokyo Metropolitan Bokuto Hospital, Tokyo, Japan.
Ryusei TamakiDepartment of Neuropsychiatry, Kyorin University Hospital, Tokyo, Japan.
Shinsuke KitoDepartment of Neuropsychiatry, Kyorin University Hospital, Tokyo, Japan.
Yoshiharu TaguchiDepartment of Neurology, Toyama University Hospital, Toyama, Japan.
Kortaro TanakaDepartment of Neurology, Toyama University Hospital, Toyama, Japan.
Naoki AtsutaDepartment of Neurology, Nagoya University, Nagoya, Japan.
Gen SobueDepartment of Neurology, Nagoya University, Nagoya, Japan.
Takayuki KondoCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Haruhisa InoueCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-4736-9537
Shoji TsujiDepartment of Neurology, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5602-5686
Isao HozumiLaboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, Gifu, Japan. hozumi@gifu-pu.ac.jp.
The University of Tokyo · JPGifu Pharmaceutical University · JPGifu University · JPKyorin University Hospital · JPKyoto University · JPNagoya University · JPTokyo Metropolitan Bokutoh Hospital · JPToyama University Hospital · JPAsahi University · JPHiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Causative genes in patients with idiopathic basal ganglia calcification (IBGC) (also called primary familial brain calcification (PFBC)) have been reported in the past several years. In this study, we surveyed the clinical and neuroimaging data of 70 sporadic patients and 16 families (86 unrelated probands in total) in Japan, and studied variants of PDGFB gene in the patients. Variant analyses of PDGFB showed four novel pathogenic variants, namely, two splice site variants (c.160 + 2T > A and c.457-1G > T), one deletion variant (c.33_34delCT), and one insertion variant (c.342_343insG). Moreover, we developed iPS cells (iPSCs) from three patients with PDGFB variants (c.160 + 2T > A, c.457-1G > T, and c.33_34 delCT) and induced endothelial cells. Enzyme-linked immunoassay analysis showed that the levels of PDGF-BB, a homodimer of PDGF-B, in the blood sera of patients with PDGFB variants were significantly decreased to 34.0% of that of the control levels. Those in the culture media of the endothelial cells derived from iPSCs of patients also significantly decreased to 58.6% of the control levels. As the endothelial cells developed from iPSCs of the patients showed a phenotype of the disease, further studies using IBGC-specific iPSCs will give us more information on the pathophysiology and the therapy of IBGC in the future.

Indexed as

MutationAdolescentAgedBasal GangliaBrain DiseasesCalcinosisEndothelial CellsFemaleHumansInduced Pluripotent Stem CellsLymphokinesMaleMiddle AgedPedigreePlatelet-Derived Growth FactorLymphokinesPlatelet-Derived Growth Factorplatelet-derived growth factor C

Identifiers

PMID30952898
PMCPMC6450963
OpenAlexW2934208478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.